Want to see PRTA full AI Analyst Report?
PRTA Stock Chart & Stats
$10.90
<$0.01(0.07%)
At close: 4:00 PM EST
$10.90
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$6.24 - $11.80
Previous CloseN/A
Volume58.73K
Average Volume (3M)732.47K
Market Cap
$453.38M
Enterprise Value$204.13
Total Cash (Recent Filing)$329.46M
Total Debt (Recent Filing)$7.65M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 10, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding52,353,237
10 Day Avg. Volume686,318
30 Day Avg. Volume732,465
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.40Price Target Upside96.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.25
Revenue Forecast (FY)$87.90M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low debt reduces refinancing and interest-rate risk, giving management flexibility to fund clinical programs or structure partnerships without immediate pressure to raise debt. This durable fiscal flexibility supports multi-year R&D timelines typical of clinical-stage biotech.
Partner-funded Collaboration ModelA business model centered on collaborations provides non-dilutive funding and external validation from large pharma partners. Such arrangements can underwrite expensive trials, allocate development risk to partners, and sustain programs through milestone-triggered funding over multiple years.
Focused Pipeline On ProteinopathiesConcentrated expertise in antibody immunotherapies for protein-misfolding diseases targets large, under-served markets (e.g., Alzheimer’s, synucleinopathies). Structural demand and high unmet need mean successful assets can generate durable commercial value and attract partnering interest.
Bears Say
Persistent Negative Cash FlowMulti-year negative operating and free cash flow signals ongoing funding needs and increases dependency on equity raises, partner payments, or debt. Chronic cash burn constrains optionality, risks dilution, and limits the firm’s ability to independently advance multiple late-stage programs.
Negative TTM Gross Profit And Deep LossesSustained negative gross profit and widening net losses indicate core operations are unprofitable and margins are not yet sustainable. This undermines long-term earnings power absent successful product commercialization or persistent external funding.
Highly Volatile, Episodic RevenueDependency on milestone and collaboration timing produces lumpy revenue that hampers predictability of cash flow and budgeting. This structural volatility complicates long-term planning, increases financing risk between milestone events, and pressures reserve management.
Prothena News
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $6.24 and its highest was $11.80 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $453.38M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Aug 10, 2026 which is in 21 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on May 07, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of -$0.348 by $0.948.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.39.
How many shares outstanding does Prothena have?
Prothena has 52,353,237 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of $0.6 in its last earnings report, beating expectations of -$0.348. Following the earnings report the stock price went up 1.996%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.40 (96.33% Upside)
$21.40 (96.33% Upside)
Hedge Fund Trend
Decreased
By 14.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.36%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
PRTA Stock 12 Month Forecast
Average Price Target
$21.40
▲(96.33% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
XOMA Royalty Corporation
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Ownership Overview
2.96% Insiders
20.11% Mutual Funds
0.35% Other Institutional Investors
65.72% Public Companies and
Individual Investors